AUS
NZ
UK
CA
USA
IND
NetScientific PLC, a venture capital group in the Technology sector, is actively advancing its portfolio of innovative companies in the UK and internationally.
NetScientific PLC has announced significant progress within its portfolio. One notable development is the alignment of its portfolio company, PDS Biotechnology, with the US Food & Drug Administration (FDA) for a phase III clinical trial of its drug aimed at treating HPV16-positive head and neck cancer. The trial will evaluate PDS's Versamune-based immunotherapy platform in combination with pembrolizumab and a triple combination therapy. The FDA has endorsed the trial's design, requested additional safety analysis, and agreed to proceed with the double combination trial (VERSATILE-003). The combination of Versamune and pembrolizumab has received fast track designation, with dose optimization to be conducted separately. PDS CEO Frank Bedu-Addo expressed gratitude for the FDA's support in developing both the double and triple Versamune HPV-based combinations and noted the initiation of the updated VERSATILE-003 study.
Additionally, NetScientific confirmed a successful £1.5 million fundraising for its portfolio company Q-Bot Limited, a robotics-as-a-service company. The fundraising, led and syndicated by EMV Capital, included a subscription for £1.25 million in new Q-Bot shares and a £250,000 loan facility, part of a refinanced loan of approximately £785,000.
Panmure Gordon has initiated coverage on NetScientific PLC (LSE:NSCI), highlighting its shift away from traditional venture capital investment models towards a focus on deep technology and life sciences sectors. The broker issued a 'buy' recommendation and a price target of 137 pence, recognizing the company's strategic evolution under the leadership of CEO Dr. Ilian Iliev since 2020. This shift aims to support innovation and growth within these sectors, further enhancing the company's value.
NetScientific continues to identify, invest in, and build high-growth companies, adding value through proactive management and advancing its portfolio to key value inflection points. The company remains committed to delivering returns through partial or full liquidity events, reinforcing its role as a significant player in the tech and life sciences investment landscape.
